Ultragenyx Pharmaceutical (RARE)

Ultragenyx Pharmaceutical (RARE) Stock Price & Analysis


RARE Stock Chart & Stats

Day’s Range$0 - $0
52-Week Range$33.36 - $68.68
Previous Close$51.82
Average Volume (3M)662.40K
Market Cap
Enterprise Value$3.04B
Total Cash (Recent Filing)$629.35M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)-5.1
Aug 03, 2023
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-10.26
Shares Outstanding70,814,462
10 Day Avg. Volume600,991
30 Day Avg. Volume662,398
Standard Deviation0.15
Financial Highlights & Ratios
Price to Book (P/B)-450.29
Price to Sales (P/S)36.52
Price to Cash Flow (P/CF)-5.80
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue7.92
Enterprise Value/Gross Profit9.49
Enterprise Value/Ebitda-4.26
Price Target Upside76.43% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering12



Risk Analysis

Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products

Product Insights

Sorry, No Data Available
There is no website visitor data available for this stock.



What was Ultragenyx Pharmaceutical’s price range in the past 12 months?
Ultragenyx Pharmaceutical lowest stock price was $33.36 and its highest was $68.68 in the past 12 months.
    What is Ultragenyx Pharmaceutical’s market cap?
    Currently, no data Available
    When is Ultragenyx Pharmaceutical’s upcoming earnings report date?
    Ultragenyx Pharmaceutical’s upcoming earnings report date is Aug 03, 2023 which is in 56 days.
      How were Ultragenyx Pharmaceutical’s earnings last quarter?
      Ultragenyx Pharmaceutical released its earnings results on May 04, 2023. The company reported -$2.33 earnings per share for the quarter, missing the consensus estimate of -$1.992 by -$0.338.
        Is Ultragenyx Pharmaceutical overvalued?
        According to Wall Street analysts Ultragenyx Pharmaceutical’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
          Does Ultragenyx Pharmaceutical pay dividends?
          Ultragenyx Pharmaceutical does not currently pay dividends.
          What is Ultragenyx Pharmaceutical’s EPS estimate?
          Ultragenyx Pharmaceutical’s EPS estimate is -$2.07.
            How many shares outstanding does Ultragenyx Pharmaceutical have?
            Ultragenyx Pharmaceutical has 70,814,460 shares outstanding.
              What happened to Ultragenyx Pharmaceutical’s price movement after its last earnings report?
              Ultragenyx Pharmaceutical reported an EPS of -$2.33 in its last earnings report, missing expectations of -$1.992. Following the earnings report the stock price went up 3.078%.
                Which hedge fund is a major shareholder of Ultragenyx Pharmaceutical?
                Among the largest hedge funds holding Ultragenyx Pharmaceutical’s share is Baker Bros Advisors LP. It holds Ultragenyx Pharmaceutical’s shares valued at 19M.


                  Ultragenyx Pharmaceutical Stock Smart Score

                  The Ultragenyx Pharmaceutical stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.
                  Learn more about TipRanks Smart Score

                  Company Description

                  Ultragenyx Pharmaceutical

                  Ultragenyx Pharmaceutical, Inc. is a biopharmaceutical company, which engages in the identification, acquisition, development and commercialization of novel products for the treatment of serious rare and ultra-rare genetic diseases. Its product includes Mepsevii and Crysvita. Mepsevii is an intravenous, which is used for the treatment of Mucopolysaccharidosis VII. Crysvita is an antibody administered via subcutaneous injection used for the treatment of XLH. The company was founded by Emil D. Kakkis on April 22, 2010 and is headquartered in Novato, CA.


                  Top 5 ETFs holding RARE

                  Market Value
                  Smart Score
                  Vanguard Health Care ETF
                  iShares Russell 1000 Growth ETF
                  iShares Core S&P Total U.S. Stock Market ETF
                  iShares Russell 1000 ETF
                  iShares U.S. Healthcare ETF
                  Up to five ETFs with an Outperform Smart Score that hold RARE. The ETFs are listed according to market value of RARE within the ETF


                  Forecast EPS vs Actual EPS

                  Similar Stocks
                  Price & Change
                  Bluebird Bio
                  Agios Pharma
                  Crispr Therapeutics AG

                  Popular Stocks

                  What's Included in PREMIUM?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis